BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Miura K, Maeda H, Morimoto N, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Goka R, Kotani K, Yamamoto H. Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities. World J Gastrointest Pathophysiol 2022; 13(3): 96-106 [PMID: 35720167 DOI: 10.4291/wjgp.v13.i3.96]
URL: https://www.wjgnet.com/2150-5330/full/v13/i3/96.htm
Number Citing Articles
1
Satoshi Oeda, Yuya Seko, Hideki Hayashi, Taeang Arai, Michihiro Iwaki, Masato Yoneda, Toshihide Shima, Kazuo Notsumata, Tadashi Ikegami, Hideki Fujii, Hidenori Toyoda, Kouichi Miura, Asahiro Morishita, Kazuhito Kawata, Kengo Tomita, Miwa Kawanaka, Hiroshi Isoda, Kanji Yamaguchi, Hideaki Fukushima, Yoshihiro Kamada, Yoshio Sumida, Shinichi Aishima, Yoshito Itoh, Takeshi Okanoue, Atsushi Nakajima, Hirokazu Takahashi. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver diseaseHepatology Research 2023; 53(6): 489 doi: 10.1111/hepr.13890
2
Mohammadjavad Sotoudeheian. Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease: Detecting Advanced Fibrosis based on Reported Liver Stiffness Measurement in FibroScan and Laboratory FindingsThe International Journal of Gastroenterology and Hepatology Diseases 2024; 3 doi: 10.2174/0126662906302851240604042954
3
Kouichi Miura, Hideki Hayashi, Yoshihiro Kamada, Hideki Fujii, Hirokazu Takahashi, Satoshi Oeda, Michihiro Iwaki, Takumi Kawaguchi, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue. Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver‐related events in nonalcoholic fatty liver diseaseHepatology Research 2023; 53(10): 978 doi: 10.1111/hepr.13938
4
Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida. Risk stratification and early detection biomarkers for precision HCC screeningHepatology 2023; 78(1): 319 doi: 10.1002/hep.32779
5
Lucia Cerrito, Irene Mignini, Maria Elena Ainora, Carolina Mosoni, Antonio Gasbarrini, Maria Assunta Zocco. Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness MeasurementCancers 2023; 15(3): 637 doi: 10.3390/cancers15030637
6
Madalina-Gabriela Taru, Monica Lupsor-Platon. Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound ElastographyCancers 2023; 15(16): 4097 doi: 10.3390/cancers15164097
7
Mohammadjavad Sotoudeheian. Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker RoleCurrent Protein & Peptide Science 2025; 26(1): 6 doi: 10.2174/0113892037315931240618085529
8
Kyaw Min Tun, Nabil Noureddin, Mazen Noureddin. Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A reviewClinical Liver Disease 2023; 22(3): 103 doi: 10.1097/CLD.0000000000000066